Gossamer Bio Shares Plunge 82% After Phase 3 PROSERA Study Misses Primary Endpoint

Gossamer Bio, Inc. (GOSS) shares collapsed 81.56 percent to $0.3929, down $1.7371 on Monday, after the company reported topline results from its Phase 3 PROSERA study of seralutinib in pulmonary arterial hypertension that narrowly missed the prespecified statistical threshold for the primary endpoint.The stock is currently trading at $0.3929, compared with a previous close of $2.1300 Nasdaq. It opened sharply lower at $0.5969 and has traded between $0.4026 and $0.6000 during the session. Trading volume has ...